Learn More
7501 Background: The proven efficacy of E in advanced NSCLC warranted its evaluation in the adjuvant setting. BR.21 data suggested pts with EGFR positive tumors (IHC/FISH) were more likely to benefit(More)
PURPOSE Although several randomized trials have been performed comparing weekly docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment of advanced non-small-cell(More)
BACKGROUND In the Iressa Pan-ASia Study (IPASS), gefitinib claimed improved progression-free survival (PFS) versus carboplatin-paclitaxel in clinically selected lung cancer patients. The primary(More)